LEXEO THERAPEUTICS INC (LXEO) Stock News

NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD

4.45 -0.31 (-6.51%)

After market: 4.3198 -0.13 (-2.93%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LXEO Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Benzinga - Mentions: NUE SF CTMX LIF

This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday

8 days ago - By: Yahoo Finance - Mentions: MSFT HSBC EBAY UNH ...

Meta, Microsoft upgraded: Wall Street's top analyst calls

a month ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

a month ago - By: Lexeo Therapeutics

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

2 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

8 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

3 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

3 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

4 months ago - By: Benzinga - Mentions: NEOG SLRX VNRX WORX ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a year ago - By: BusinessInsider

News Image

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024

a year ago - By: InvestorPlace

LXEO Stock Earnings: Lexeo Therapeutics Beats EPS for Q2 2024

4 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

5 months ago - By: MarketBeat - Mentions: TNXP

Pharma Frenzy: Volatility Ignites Biotech Sector

5 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

7 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

9 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

9 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

10 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference

a year ago - By: Lexeo Therapeutics

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

a year ago - By: Lexeo Therapeutics

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights